您好,欢迎来到试剂信息网! [登录] [免费注册]
试剂信息网
位置:首页 > 产品库 > MLi-2
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
MLi-2
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
MLi-2图片
CAS NO:1627091-47-7
包装与价格:
包装价格(元)
2 mg电议
5 mg电议
10 mg电议
25 mg电议
50 mg电议
100 mg电议
200 mg电议
1 mL*10 mM(in DMSO)电议

产品介绍
MLi-2 是一种结构新颖、高效、选择性的 LRRK2 激酶抑制剂,具有中枢神经系统活性,IC50为 0.76 nM,有潜力用于帕金森氏病。

产品描述

MLi-2 is a structurally novel, highly potent, and selective LRRK2 kinase inhibitor with central nervous system activity. MLi-2 exhibits exceptional potency in a purified LRRK2 kinase assay in vitro (IC50 = 0.76 nM), a cellular assay monitoring dephosphorylation of LRRK2 pSer935 LRRK2 (IC50 = 1.4 nM), and a radioligand competition binding assay (IC50 = 3.4 nM).

体外活性

MLi-2, a structurally novel, highly potent, and selective LRRK2 kinase inhibitor with central nervous system activity.?MLi-2 exhibits exceptional potency in a purified LRRK2 kinase assay in vitro (IC50 = 0.76 nM), a cellular assay monitoring dephosphorylation of LRRK2 pSer935 LRRK2 (IC50 = 1.4 nM), and a radioligand competition binding assay (IC50 = 3.4 nM).?MLi-2 has greater than 295-fold selectivity for over 300 kinases in addition to a diverse panel of receptors and ion channels.

体内活性

MLi-2, a structurally novel, highly potent, and selective LRRK2 kinase inhibitor with central nervous system activity.?MLi-2 exhibits exceptional potency in a purified LRRK2 kinase assay in vitro (IC50 = 0.76 nM), a cellular assay monitoring dephosphorylation of LRRK2 pSer935 LRRK2 (IC50 = 1.4 nM), and a radioligand competition binding assay (IC50 = 3.4 nM).?MLi-2 has greater than 295-fold selectivity for over 300 kinases in addition to a diverse panel of receptors and ion channels.

Cas No.

1627091-47-7

分子式

C21H25N5O2

分子量

379.46

储存和溶解度

DMSO:60 mg/mL (158.12 mM),Need ultrasonic
Powder: -20°C for 3 years
In solvent: -80°C for 2 years